Literature DB >> 8939955

Threonine 1342 in human topoisomerase IIalpha is phosphorylated throughout the cell cycle.

R Ishida1, M Iwai, K L Marsh, C A Austin, T Yano, M Shibata, N Nozaki, A Hara.   

Abstract

To investigate the relationship between the modulation of topoisomerase II activity and its phosphorylation state during the cell cycle, a monoclonal antibody against C-terminal peptide (residues 1335-1350) of topoisomerase IIalpha containing a consensus sequence of casein kinase II, TDDE and its phosphorylated threonine were prepared. In an enzyme-linked immunosorbent assay, the antibody, named PT1342, recognized the immunogenic phosphopeptide but not the non-phosphorylated form of the peptide. The PT1342 antibody reacted only with a 170-kDa protein from HeLa cells and recognized anti-topoisomerase IIalpha immunoprecipitants. Furthermore, the antibody did not react with the human topoisomerase IIalpha mutated at codon 1342 from threonine to alanine, showing that PT1342 was directed against the phosphorylated threonine 1342. To examine the level of phosphorylation of threonine 1342 of topoisomerase IIalpha through the cell cycle, HeLa cells were stained simultaneously for phosphorylated topoisomerase IIalpha and DNA and analyzed by flow cytometry. Cells in the G2-M phase contained about double the PT1341-reacted topoisomerase IIalpha than did cells in G1 or S phases. The antibody stained the nuclei in interphase and mitotic chromosomes and its periphery, as seen with anti-topoisomerase IIalpha antibody. Thus, threonine 1342 in topoisomerase IIalpha is phosphorylated throughout the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939955     DOI: 10.1074/jbc.271.47.30077

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Proteomic analysis of human metaphase chromosomes reveals topoisomerase II alpha as an Aurora B substrate.

Authors:  Ciaran Morrison; Alexander J Henzing; Ole Nørregaard Jensen; Neil Osheroff; Helen Dodson; Stefanie E Kandels-Lewis; Richard R Adams; William C Earnshaw
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

Review 2.  Topoisomerase II: untangling its contribution at the centromere.

Authors:  Andrew C G Porter; Christine J Farr
Journal:  Chromosome Res       Date:  2004       Impact factor: 5.239

3.  Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Authors:  Adrian G Grozav; Belinda B Willard; Toshiyuki Kozuki; Kenichi Chikamori; Marius A Micluta; Andrei-Jose Petrescu; Michael Kinter; Ram Ganapathi; Mahrukh K Ganapathi
Journal:  Proteomics       Date:  2011-01-31       Impact factor: 3.984

4.  Human topoisomerase IIalpha: targeting to subchromosomal sites of activity during interphase and mitosis.

Authors:  Marta Agostinho; José Rino; José Braga; Fernando Ferreira; Soren Steffensen; João Ferreira
Journal:  Mol Biol Cell       Date:  2004-02-20       Impact factor: 4.138

5.  Prokaryotic expression and preparation of polyantibody of human histydyl-tRNA synthetase related gene.

Authors:  Xianfang Meng; Jing Shi; Xiaochun Liu; Jinzhong Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

6.  Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.

Authors:  Adrian G Grozav; Kenichi Chikamori; Toshiyuki Kozuki; Dale R Grabowski; Ronald M Bukowski; Belinda Willard; Michael Kinter; Anni H Andersen; Ram Ganapathi; Mahrukh K Ganapathi
Journal:  Nucleic Acids Res       Date:  2008-11-29       Impact factor: 16.971

7.  The impact of the human DNA topoisomerase II C-terminal domain on activity.

Authors:  Emma L Meczes; Kathryn L Gilroy; Katherine L West; Caroline A Austin
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

Review 8.  Topoisomerase IIα in chromosome instability and personalized cancer therapy.

Authors:  T Chen; Y Sun; P Ji; S Kopetz; W Zhang
Journal:  Oncogene       Date:  2014-10-20       Impact factor: 9.867

9.  Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.

Authors:  Y Matsumoto; H Takano; K Kunishio; S Nagao; T Fojo
Journal:  Jpn J Cancer Res       Date:  2001-10

10.  Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.

Authors:  Y Matsumoto; H Takano; K Kunishio; S Nagao; T Fojo
Journal:  Jpn J Cancer Res       Date:  2001-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.